Literature DB >> 22142822

Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.

Abdelhamid Beji1, David Horst, Jutta Engel, Thomas Kirchner, Axel Ullrich.   

Abstract

PURPOSE: Abnormal accumulation and dysregulation of the epidermal growth factor receptor family member HER3 is associated with the development of various human cancers including those of the breast, lung, and ovary. We have previously shown that in melanoma HER3 is frequently overexpressed and is associated with poor prognosis. However, the importance of HER3 in colon cancer and its putative prognostic significance is still unknown. EXPERIMENTAL
DESIGN: HER3 expression was analyzed in primary colon tumors from 110 patients by immunohistochemistry and correlated with time of progression. Parallel to this, the influence of HER3 overexpression on cell proliferation, migration, invasion, and apoptosis was investigated in four different colon cancer cell lines including DLD-1, LoVo, CaCO2, and T-84.
RESULTS: HER3 was detected at high frequency and exclusively at the membrane of the primary tumors. Elevated HER3 expression levels may serve as a putative prognostic marker because it associates with cell proliferation and decreased time to disease progression. High HER3 protein expression as well as phosphorylation levels were detected in tested cells. HER3 downregulation by RNA interference abrogated cell proliferation, migration, and invasion. In addition, suppression of HER3 resulted in a G(2)-M cell-cycle arrest, induced apoptosis, and led to morphologic changes in colon cancer cell lines. Furthermore, application of a monoclonal antibody specific to the extracellular portion of the receptor reduced heregulin-β1-induced migration and invasion and also induced apoptosis in colon cancer cell lines.
CONCLUSION: We postulate that HER3 is critically involved in colon cancer progression and may serve as a novel target for therapeutic intervention. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22142822     DOI: 10.1158/1078-0432.CCR-11-1186

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Authors:  Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

2.  HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.

Authors:  An Na Seo; Yoonjin Kwak; Woo Ho Kim; Duck-Woo Kim; Sung-Bum Kang; Gheeyoung Choe; Hye Seung Lee
Journal:  Virchows Arch       Date:  2015-03-05       Impact factor: 4.064

3.  MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures.

Authors:  Xin Liu; Jessica K Lukowski; Colin Flinders; Seungil Kim; Rebecca A Georgiadis; Shannon M Mumenthaler; Amanda B Hummon
Journal:  Anal Chem       Date:  2018-12-07       Impact factor: 6.986

4.  Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

Authors:  Martin Bezler; Jan G Hengstler; Axel Ullrich
Journal:  Mol Oncol       Date:  2012-07-20       Impact factor: 6.603

5.  Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.

Authors:  Hester A Doyle; Raymond A Koski; Nathalie Bonafé; Ross A Bruck; Stephanie M Tagliatela; Renelle J Gee; Mark J Mamula
Journal:  Cancer Immunol Immunother       Date:  2018-07-28       Impact factor: 6.968

6.  Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Authors:  Georgina Meneses-Lorente; Thomas Friess; Irene Kolm; Gabriele Hölzlwimmer; Sabine Bader; Christophe Meille; Marlene Thomas; Birgit Bossenmaier
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-22       Impact factor: 3.333

7.  Prognostic impact of Metadherin-SND1 interaction in colon cancer.

Authors:  Nan Wang; Xilin Du; Li Zang; Nuan Song; Tao Yang; Rui Dong; Tao Wu; Xianli He; Jianguo Lu
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

8.  Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

Authors:  Yassamine Lazrek; Olivier Dubreuil; Véronique Garambois; Nadège Gaborit; Christel Larbouret; Christophe Le Clorennec; Gaelle Thomas; Wilhem Leconet; Marta Jarlier; Martine Pugnière; Nadia Vié; Bruno Robert; Céline Monnet; Khalil Bouayadi; Hakim Kharrat; Philippe Mondon; André Pèlegrin; Thierry Chardès
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

9.  Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.

Authors:  Stephanie N Brosius; Amy N Turk; Stephanie J Byer; Nicole M Brossier; Latika Kohli; Amber Whitmire; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Acta Neuropathol       Date:  2014-04       Impact factor: 17.088

10.  Expression, purification, crystallization and preliminary X-ray analysis of the HER3-9E12 Fab complex.

Authors:  Kecheng He; Ang Huang; Yong Huang; Hiroaki Takeda
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-05-24       Impact factor: 1.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.